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Lela A. Lee
Neonatal lupus erythematosus (NLE) is an autoimmune disease whose major findings are subacute cutaneous lupus
erythematosus (SCLE) skin lesions and congenital heart block. Babies have maternal anti-Ro/SSA, anti-La/SSB, or anti-U1RNP
autoantibodies. Anti-Ro/SSA are the predominant autoantibodies, having been found in about 95% of cases. The autoantibodies
pass through the placenta from mother to child. Skin disease resolves at about the time that maternal autoantibodies can no
longer be detected in the baby. NLE therefore provides the strongest clinical evidence that autoantibodies are involved in at least
some manifestations of lupus erythematosus, but there is as yet no definitive evidence implicating autoantibodies in the disease
process. Skin disease usually begins after birth, is transient, and does not result in scarring. Cardiac disease begins in utero, and
the heart block is almost always permanent. Many babies require pacemakers, and about 10% die from complications related to
cardiac disease. In some cases, transient liver disease or thrombocytopenia have been observed. Individuals who had NLE usually
have healthy childhoods but may develop autoimmune disease in adulthood. Whether the later development of autoimmune
disease is a common or an unusual event is not yet known. Mothers of babies with NLE may be asymptomatic initially, but with
time usually develop symptoms of autoimmune disease. The most typical constellation of symptoms in our group of
approximately 30 mothers of babies with NLE is that of Sjo¨gren’s syndrome. Most babies exposed to anti-Ro/SSA autoantibodies
during gestation will not develop NLE. There is no test to determine prospectively which babies will be affected. Treatment during
gestation is still controversial and, if attempted, should be reserved for fetuses with potentially life-threatening disease. Treatment
after birth consists of topical management for skin disease and pacemaker implantation, if necessary, for heart block. Systemic
steroids may be given for serious internal disease. J Invest Dermatol 100:9S–13S, 1993
Neonatal lupus erythematosus (NLE) is an uncommon autoimmune
disease whose skin findings are analogous to those of subacute cutaneous
lupus erythematosus (SCLE) of adults. Babies with this disease typically
have nonscarring lesions of SCLE or congenital heart block, or both.
Mothers of babies with NLE usually have IgG anti-Ro/SSA autoantibodies.
These autoantibodies pass through the placenta to the baby and may be
important in initiating the disease. NLE has been of considerable interest
not only in its own right but also because of the expectation that it will
help clarify the pathogenesis of other forms of lupus.
HISTORY AND INCIDENCE
Much of what we know about NLE is a result of relatively recent
observations. In 1928, Alyward reported siblings with congenital heart
block [1]. The fact that the mother had Sjo¨gren’s syndrome was
mentioned, but there was no association made between autoimmune
disease in the mother and congenital heart block in her offspring, and
several decades would pass before such a relationship would be
discovered [2,3]. McCuistion and Schoch were the first to report cutaneous
LE in a newborn [4]. Because the baby’s lesions resolved, after which the
baby appeared to be healthy, and because the mother developed systemic
lupus erythematosus (SLE), they postulated that a factor transferred from
mother to child caused the skin lesions in the baby. In 1980, Franco,
Weston, and co-workers reported an association between anti-Ro/SSA
autoantibodies and NLE [5,6]. The discovery of a serologic marker for NLE
led to increased recognition and reporting of this disease. In 1983, two
groups reported evidence that most babies who would previously have
been classified as having idiopathic congenital heart block actually have
maternal anti-Ro/SSA autoantibodies and therefore have NLE [7,8].
The incidence of NLE is not known. However, there is information
concerning the incidence of congenital heart block. One estimate is that
congenital heart block occurs in 1 of 20,000 live births [9]. Because NLE
is a common cause of congenital heart block, and because heart block
accounts for perhaps half the cases of NLE, it is reasonable to assume that
the incidence of NLE is likely to be at least 1 in 20,000 live births.
CLINICAL FINDINGS IN BABIES
About half of the NLE cases reported exhibited skin disease and about
half exhibited congenital heart block. Approximately 10% of cases had
both skin disease and heart block. Liver disease and thrombocytopenia
have also been observed. In our series of more than 30 babies with NLE,
we have observed the following combinations of clinical findings: skin
disease alone; congenital heart block alone; skin disease and heart block;
skin and liver disease; skin disease, liver disease, and thrombocytopenia;
skin disease, heart block, and thrombocytopenia; heart block and liver
disease; and heart block, liver disease, and thrombocytopenia. Thus, in a
given baby, any combination of findings is possible.
Skin Disease Cutaneous lesions are erythematous plaques that are often
scaly and round or elliptical (Fig 1). As is the case with SCLE in adults,
typical lesions have relatively few inflammatory cells and do not feel
indurated to palpation. Also similar to SCLE of adults is lack of scarring,
follicular plugging, and dermal atrophy, and the common findings of
hypopigmentation and epidermal atrophy. Unlike SCLE in adults, NLE
lesions are most frequently found on the face and scalp. On occasion,
lesions are concentrated in the periorbital or malar regions. Although many
babies have lesions predominantly on the head, widespread involvement
may occur.
In cases of NLE reported in Japan, typical cutaneous findings consist
of annular erythema with a more intense inflammatory infiltrate than
described above [10]. Clinically, the lesions are more similar to reactive
erythemas than to papulosquamous SCLE. Thus, there may be substantial
differences in the cutaneous morphology of NLE in different regions of
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the world. (Note: a similar annular erythema has been reported in
Japanese adults who have Sjo¨gren’s syndrome).
In our group of NLE patients with skin disease, it is common for sun
exposure to induce or exacerbate lesions. It is certainly plausible that the reason
lesions occur more frequently on the head is that that area generally receives
more sun exposure in babies than does any other area of skin. However, sun
exposure is almost certainly not required for lesions to occur. NLE skin lesions
have been reported to be present at birth, for example, and lesions may occur
in the relatively protected areas of skin such as the diaper area.
The natural history of NLE skin lesions is that they are transient.
Lesions appear at birth or, more commonly, within a few weeks of birth.
The lesions usually last a few weeks or months. In most of the cases we
have observed, disease activity resolved by six months of age. Although
inflammation and appearance of new lesions generally resolve promptly,
hypopigmentation may take many months to resolve. In the 16 cases for
which we have adequate follow-up, 13 children had no residual
evidence of NLE skin disease, two had persistent small telangiectasias,
and one had a small patch of hyperpigmentation. We have not observed
scarring or atrophy in any child with NLE.
Once the diagnosis of NLE is suspected, the sera of the baby and mother
should be examined for autoantibodies. In about 95% of cases reported, the
autoantibodies found in NLE are anti-Ro/SSA [11]. Anti-La/SSB autoanti-
bodies are also found in a substantial percentage of patients. A few babies
with NLE have had only anti-La/SSB autoantibodies detected by immuno-
diffusion, and more sensitive tests have been required to demonstrate anti-
Ro/SSA. Because anti-La/SSB autoantibodies rarely, if ever, occur in the
absence of anti-Ro/SSA, it can be presumed that a baby who has anti-La/SSB
also has anti-Ro/SSA. Two cases have been reported, and more have since
been seen, of babies with cutaneous NLE who have anti-U1RNP
autoantibodies in the absence of anti-Ro/SSA and anti-La/SSB [12], The
possibility that other autoantibodies could be related to NLE cannot be
excluded. Nevertheless, the presence of anti-Ro/SSA, anti-La/SSB, or anti-
U1RNP autoantibodies together with appropriate clinical findings is strong
evidence in favor of the diagnosis of NLE, and their absence can be
considered strong evidence against the diagnosis of NLE.
Biopsy of lesional skin can provide important documentation of the
diagnosis of cutaneous NLE. The histology we have observed is consistent
with SCLE [13], with prominent features being basal cell damage in the
epidermis and a relatively sparse mononuclear infiltrate in the superficial
dermis. The immunofluorescent findings we have observed are consistent
with what we have described in SCLE, namely, a particulate deposit of IgG
in the epidermis [14,15]. Because the skin findings are fairly distinctive,
photographs can be helpful as documentation of the diagnosis.
Heart Disease The cardiac lesion in NLE is characteristically an isolated
(i.e., unassociated with other cardiac anomalies) complete heart block that
begins during gestation. A few cases of probable NLE have had lesser
degrees of heart block [16]. (Note: the term ‘‘probable’’ cardiac NLE refers
to cases of heart block likely to be NLE either because the heart block was
isolated or because the mother had connective tissue disease, but for
which the diagnosis was not confirmed by testing for autoantibodies.)
Although other cardiac anomalies are not generally observed, there have
been a few cases of persistent patent ductus arteriosus in babies with
probable or definite cardiac NLE with heart block [16–19].
Heart block has been detected as early as the sixteenth week of
gestation but may appear later in gestation. In one case where the mother
was followed closely during pregnancy, heart block was not detectable
until the twenty-fourth week of gestation [20]. There has also been one
case in which heart block progressed from second-degree block, present at
birth, to third-degree block by 9 weeks of age [21]. Thus, it would appear
that the conduction system is vulnerable to the development of heart block
from the time the conduction system develops until shortly after birth.
The major histologic findings in the conduction system are fibrosis
and calcifications replacing the atrioventricular node [22,23]. In some
cases the sinoatrial node has also been involved [17,24], There may be
patchy lymphocytic infiltrates in the myocardium [24,25], a finding that
is difficult to evaluate because normal myocardium may occasionally
have small patches of lymphocytes. Endocardial fibroelastosis, a
nonspecific finding, is also occasionally described [2,3]. (It should be
noted that histologic findings are from postmortem examinations and
therefore apply to the severe end of the spectrum of cardiac NLE.)
Because of the fibrosis in the conduction system, heart block is almost
always permanent. There has been one case of probable NLE in which a
baby had transient atrioventricular dissociation, followed by first-degree
heart block, then a normal sinus rhythm [26]. Despite having an
exceptionally slow heart rate, approximately half of babies with heart
block due to NLE are well compensated and do not require treatment. The
other half need pacemaker implantation. About 10% of babies with heart
block do not respond even to pacemaker implantation, probably because
of coexistent myocardial disease, and die of intractable heart failure.
The diagnosis of heart block may be suspected during routine obstetric
examination because the fetal heart rate will be slow. That the slow heart
rate is due to heart block can be confirmed by fetal ultrasound, where the
atria and ventricles can be observed to be beating at different rates.
Ultrasound can also be used to detect other structural cardiac abnormalities.
In cases where the physical findings are consistent with cardiac NLE, the
diagnosis can be confirmed by testing the mother for autoantibodies, as
described above.
Other Findings Liver disease has occurred in several cases of NLE [27,28]. In
our group, there have been four cases of non-infectious hepatitis. In two of
those cases, the baby also had intractable heart failure and died in the
neonatal period. The other two babies had skin but not cardiac involvement,
and the liver disease lasted a few weeks, after which there was apparently a
full recovery.
Thrombocytopenia has been observed in several cases of NLE
[28–32]. Although thrombocytopenia may occur as a nonspecific finding
in seriously ill babies, many or most of the cases reported in babies with
NLE probably are related directly to the NLE. Petechiae or purpura may
be a presenting sign of NLE. In our group, thrombocytopenia was present
in three babies, including two siblings. In one baby gastrointestinal
bleeding was thought to be related to the thrombocytopenia.
In our cases, the liver disease and thrombocytopenia were often not
evident at birth. Rather, physical findings suggestive of liver disease or
thrombocytopenia became evident a few weeks after birth, and disease
activity resolved within a few more weeks. Thus, the course of liver
disease and thrombocytopenia was similar to that of skin disease.
There have been case reports of hemolytic anemia, leukopenia,
splenomegaly, pneumonitis, hypocalcemia, or myelopathy occurring in
Figure 1. Cutaneous lesions of NLE. Lesions shown here are erythematous
elliptical plaques with central hypopigmentation. The major sites affected in
this baby were the forehead and periorbital skin.
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association with NLE. Whether these were related or incidental findings
is not yet clear.
Long-Term Prognosis Babies with NLE who survive the neonatal period
usually have reasonably healthy childhoods. We examined symptoms in 24
children who had NLE in a study where the follow-up averaged 5 years [28].
Three babies with heart disease died in infancy. Of the 21 surviving children,
nine had skin disease only, nine had heart block only, one had skin and liver
disease, one had skin disease and heart block, and one had skin disease, heart
block, and thrombocytopenia. All of the surviving children were in good
health on follow-up, although five children had permanent pacemakers.
In another study of 27 cases of congenital heart block, most of whom
probably had NLE, most children were free of symptoms [18]. However,
three babies died in the neonatal period and one died at age 6 months
from a Stokes-Adams attack. One child needed a pacemaker implanted at
age 2 years because of Stokes-Adams attacks. Another child needed
pacemaker implantation at age 3 and was experiencing increasing heart
failure at age 8 years. Thus, some babies with heart block do experience
continuing difficulties in childhood.
The outlook for adolescence and adulthood in individuals who had
NLE is not known. There have been at least two cases of individuals who
had cutaneous NLE developing connective tissue disease in adulthood
[33,34], and five cases of individuals who had isolated congenital heart
block developing connective tissue disease [18,26,35,36].
CLINICAL FINDINGS IN MOTHERS
Symptoms Approximately half of the mothers in our series were
asymptomatic at the time of delivery of their first baby with NLE. With
time, many of the initially asymptomatic mothers develop symptoms. We
conducted a follow-up study of 21 mothers who had babies with NLE [28].
About half were asymptomatic at the time of delivery of the first baby with
NLE. However, at the time of follow-up, averaging 5 years after delivery,
18 had symptoms suggestive of autoimmune disease. The symptoms were
arthralgias (n¼ 13), dry eyes (n¼12), and dry mouth (n¼11), symptoms
suggestive of Sjo¨gren’s syndrome. One mother had SLE and one had SCLE.
Two had transient lesions suggestive of leukocytoclastic vasculitis,
although the diagnosis was not documented. Most of the mothers had
mild symptoms, but since that report two mothers have had debilitating
symptoms. Although the outlook for mothers appears to be generally good,
there is a possibility for the development of serious autoimmune disease.
Obstetric Histories In the study of 21 NLE mothers cited above, obstetric
histories were evaluated. These mothers did not have an increased risk for
spontaneous abortion. Although it appears likely from our data that there is
not a substantial risk for early fetal loss, there is certainly a risk for death in
the newborn period from heart disease, and some of the babies with heart
block and heart failure have had their course complicated by prematurity.
In 11 of 21 women, 13 pregnancies occurred subsequent to the birth
of their first baby with NLE. Of these pregnancies, one resulted in
spontaneous abortion, nine resulted in normal babies, and three resulted
in babies with NLE. One of the women had seven children, the fourth
and seventh of whom had heart block. Thus, the risk for having another
baby with NLE is significant but far less than 100%.
MANAGEMENT
During Gestation Testing for autoantibodies during pregnancy is
appropriate for those women who have diseases or symptoms associated
with anti-Ro/SSA autoantibodies, in particular, Sjo¨gren’s syndrome,
SCLE, SLE, arthralgias, dry eyes, dry mouth, or photosensitivity. Women
who have previously given birth to a baby with heart block or with other
signs or symptoms suggestive of NLE should be screened. Screening tests
should include fluorescent anti-nuclear antibodies and testing specifi-
cally for anti-Ro/SSA, anti-La/SSB, and anti-U1RNP autoantibodies.
The most important aspect of screening is good obstetrical care. The
one sign of NLE that can be detected during gestation is heart disease,
and that can be detected during the course of routine prenatal care by
finding a slow fetal heart rate (see heart disease above). If heart block is
confirmed, the fetus should then be followed closely for the development
of hydrops fetalis and the delivery room personnel should be prepared for
management of a newborn who may have heart failure.
There are several factors to weigh in determining whether to attempt
therapeutic interventions during pregnancy. First, most women who have
anti-Ro/SSA autoantibodies will have normal babies. The risk for having a
baby with NLE if the mother has anti-Ro/SSA is not known. However, in an
unselected group of 800 pregnant women, we found anti-Ro/SSA
autoantibodies in four (0.5%) and anti-La/SSB autoantibodies in one
(0.1%), using immunodifFusion in agarose as the testing assay [37]. The
implication of this, taken together with the approximated incidence of NLE,
is that about 1–2% of unselected women with anti-Ro/SSA will have a baby
with NLE. It should be emphasized that this is a very rough estimate, but the
major point is the generally good outcome for women with anti-Ro/SSA.
Certain groups of anti-Ro/SSA positive women appear to be at a
higher risk for having a baby with NLE. For example, given the data
presented in a preceding section, mothers who have previously had a
baby with NLE have approximately a 25% chance of having another
baby with NLE in a subsequent pregnancy [28]. Also, women who have
SLE may be at higher risk. In a group of women with SLE and anti-Ro/SSA,
six of 96 pregnancies (6%) resulted in babies with congenital heart block
[38]. In another group of women with SLE and anti-Ro/SSA, three of 24
babies (13%) had definite NLE and another three (13%) had possible NLE
[39]. (‘‘Possible’’ NLE babies had thrombocytopenia only, hemolytic
anemia only, or equivocal carditis without heart block.) Even for these
high risk groups, though, the majority of babies born will not have NLE.
A second factor to consider before attempting treatment is that, of
those babies who develop NLE, about half will have skin disease, which
is benign. In babies who have potentially life-threatening manifestations,
the estimated mortality rate is substantial but low, about 10%.
Given the above, it would seem most reasonable to consider therapy
only in those situations in which the fetus already has evidence of a
potentially life-threatening disease, and the risks to both the mother and
fetus should be carefully considered. Serial plasmapheresis and systemic
steroid treatment of the mother have been tried. In one case, pleural and
pericardial effusions resolved during treatment [20]. Because such an
event could have occurred spontaneously, it is not clear that the treatments
altered the natural course of the disease. The most encouraging report is of
a case in which heart block resolved following treatment of the mother
with systemic steroids [40]. That seems unlikely to have occurred by
chance alone, although, as previously mentioned, there has been a case
reported of heart block that reverted to normal sinus rhythm.
After Birth Newborns who are suspected of having NLE or who are
known to have autoantibodies associated with NLE should be examined
for the presence of skin disease, heart disease (including first- and
second-degree heart block), liver disease, and thrombocytopenia. Such
evaluation would include a physical examination, electrocardiography,
complete blood count with platelet count, and liver function tests (e.g.,
bilirubin, glutamic oxaloacetic transaminase, and alkaline phosphatase).
Management of skin disease consists of protection from sun exposure
and use of non-fluorinated topical steroids. Systemic treatment is not
indicated, primarily because of the risks associated with systemic
treatment [41] and the benign nature of the skin disease. In addition,
antimalarials, the mainstay of systemic therapy for SCLE in adults, take
some time to work, and may not be effective until the skin disease in NLE
is already spontaneously resolving.
Treatment of heart disease is not always necessary, as mentioned
above. For those children with heart failure due to a slow heart rate,
pacemaker implantation is the treatment of choice. Children who have
heart failure even after pacemaker implantation and children who have
other serious internal manifestations of NLE may be treated with systemic
steroids. The efficacy of systemic steroids is difficult to assess in a
situation where the disease activity typically regresses spontaneously.
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PATHOGENESIS
NLE provides a unique insight into the pathogenesis of LE. First, it
implicates a factor that is transferrable across the placenta. Second, it
illustrates that the pathogeneses of different clinical manifestations of LE
may be different. It would appear, for example, that the pathogenesis of
SCLE is substantially different from that of scarring discoid lupus
erythematosus (DLE). Whereas many newborns have now been observed
with nonscarring SCLE lesions, scarring DLE lesions have not been noted.
It would seem that SCLE skin lesions can be initiated by a factor that
crosses the placenta, whereas DLE cannot.
Mothers of babies with NLE almost always have antibodies to Ro/SSA,
autoantibodies which have a strong clinical association with SCLE. These
IgG autoantibodies are passed through the placenta and can be found in
the children’s sera. The skin lesions are temporary and begin to resolve at
or before the time that maternal autoantibodies are no longer found in the
children. It would appear from the regular presence of the autoantibodies
and the timing of the cutaneous disease that the maternal anti-Ro/SSA
autoantibodies are pathogenic. It is intriguing, though, that mothers of
babies with NLE usually do not have SCLE and never have heart block.
Thus, mothers presumably exposed to the same IgG autoantibodies as their
children do not develop the same sort of disease. Nor do siblings, even
fraternal twins, of babies with NLE necessarily develop NLE. In addition,
infusion of guinea pigs with maternal NLE sera leads to antibody
deposition in tissues but has not yet resulted in the clinical findings of
NLE. Clearly, if autoantibodies are involved, the mechanism of injury is
complex and is not simply a matter of exposure of tissue to autoantibodies.
Even though autoantibodies may not provide a simple explanation of
NLE, there is evidence that autoantibodies may be involved. First, IgG
antibodies have been demonstrated in NLE lesions. In the skin, the
characteristic finding in our observations is a paniculate deposit of IgG in
the epidermis. The pattern is similar to that we have described in SCLE in
adults [14,15]. We described similar paniculate deposits of IgG in the
conduction system and myocardium of a baby who died of heart block
and myocardial disease [25]. This paniculate pattern of deposition was
also seen when guinea pigs were infused with anti-Ro-containing NLE
maternal sera [42].
There is evidence that the antibodies responsible for the paniculate
deposits in the skin are anti-Ro/SSA [14,43]. We grafted immunodeficient
mice with human skin and then gave a parenteral injection of NLE
maternal antiserum or purified antibodies. When the human skin grafts
were examined for human IgG, paniculate deposits were found in the
epidermis with NLE maternal sera and with affinity-purified anti-Ro/SSA
autoantibodies, but not with control sera. When NLE serum was
adsorbed to a Ro/SSA affinity column to remove selectively the anti-
Ro/SSA antibodies, antibody binding was not seen in the skin graft. Thus,
the factor responsible for the paniculate IgG epidermal deposits was anti-
Ro/SSA. (Note: the antisera tested did not contain significant amounts of
anti-La/SSB or anti-U1RNP, so the deposition of these autoantibodies in
the skin has not been specifically tested.)
The reasons for the frequency with which the skin and heart are
affected in NLE are not known. In the guinea pig studies, antibodies were
found in multiple internal organs, not just those likely to be affected in
NLE. Studies of the antigens present in skin and heart have not disclosed
any unique antigens in those locations [44–46].
The explanation for some children developing skin disease only and
others developing heart disease only is also elusive. Studies of the
antibody specificities in NLE heart disease sera and NLE skin disease sera
have not detected any significant differences between those groups [44].
There is some evidence that IgG subclasses cross the placenta at different
rates, with IgGl crossing well relatively early in pregnancy. We examined
IgG subclasses in NLE heart disease sera and NLE skin disease sera to
determine whether the heart disease sera would be more likely to have a
subclass that crosses the placenta well at a time when heart block is likely
to form [47]. Both heart and skin disease sera had predominantly IgGl.
Thus, differences in subclasses were not the explanation for the clinical
differences.
The likelihood that a factor passed through the placenta from the
mother to the baby is responsible for initiating NLE has focused attention
toward autoantibodies and away from lymphocytes. However, lympho-
cytic infiltrates are seen in the skin in NLE lesions and are likely to be
contributing to the disease process. Their presence in the heart has been,
for the most part, minimal, and the possibility of finding lymphocytes in
normal myocardium has complicated evaluation of the contribution of
those cells to the cardiac disease process.
Complement deposition is found in skin and heart lesions of NLE,
although we have also found complement deposition in normal skin in
adults with SCLE [15]. It is intriguing, though unexplained, that abnormal
C4 genes are seen in a significant number of NLE mothers [48]. This may
result in abnormal C4 function, which could play a role in disease.
Alternatively, the C4 gene may be near an NLE-related gene on the
chromosome.
Other genetic factors are important in NLE. Mother of babies with
NLE have an increased likelihood of being HLA-B8, DR3 positive [49].
This is probably a reflection of the role that HLA proteins play in antigen
recognition. Certain configurations of HLA are likely to provide optimal
recognition of Ro/SSA protein.
Sex steroids are probably important in the disease process, because
cutaneous NLE is more common in female than in male subjects by a ratio
of about 3:1. It is interesting that the ratio is closer to 1:1 for heart block.
This observation could be related to the fact that heart block occurs in
utero, where the hormonal milieu is different from that after birth.
Sun exposure may exacerbate or initiate skin lesions, but seems
unlikely to be necessary for lesions to form in all cases, as mentioned
previously. More detailed discussion of sunlight and cutaneous LE is to be
found in later articles in this issue.
In summary, NLE is perhaps the best clinical indicator that auto-
antibodies are involved in. the pathogenesis of SCLE skin lesions. Although
the evidence implicating autoantibodies is strong, it is not conclusive. The
process that leads to NLE appears to be multifactorial and may involve
autoantibodies, lymphocytes, complement, sex steroids, and/or sunlight.
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